European Healthtech startup funding raised during H1 2013.
In H1 2013, 56 European Healthtech companies raised a combined €419M across 59 funding rounds, up 123.0% versus H1 2012. Finland led by capital raised, and Lanzadera was the most active investor. Data as of 7 Aug 2026.
| Company | Stage | Date | Amount |
|---|---|---|---|
| Biotie Therapies | Grant | Jun 2013 | €111M |
| Symphogen | Growth/Late | May 2013 | €41M |
| Auris Medical | Series C | Apr 2013 | €40M |
| Opsona | Series C | Apr 2013 |
| €33M |
| GenSight Biologics | Series A | Apr 2013 | €32M |
| STAT-Diagnostica | Series B | May 2013 | €22M |
| Genticel | Series D+ | Apr 2013 | €18M |
| Phagenesis | Series B | May 2013 | €15M |
| vitrolife.com | Growth/Late | Mar 2013 | €15M |
| Treato | Series B | Apr 2013 | €11M |
| EyeTechCare | Series C | Mar 2013 | €10M |
| Dysis Medical | Early VC | Apr 2013 | €8.8M |
| Horizon Discovery | Series C | Jun 2013 | €8.1M |
| Sofinnova Partners | Other | Apr 2013 | €8.0M |
| eZono | Early VC | Jan 2013 | €7.6M |
